Comparative Pharmacology
Head-to-head clinical analysis: CEDILANID D versus LANOXICAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDILANID D versus LANOXICAPS.
CEDILANID-D vs LANOXICAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Digitalis glycoside; inhibits Na+/K+-ATPase, increasing intracellular calcium and cardiac contractility.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
0.05 to 0.2 mg intravenously or intramuscularly, administered slowly over 5 minutes; initial dose 0.15 to 0.2 mg, then 0.1 to 0.15 mg every 30 minutes up to a total of 0.4 mg. Oral: 0.05 to 0.2 mg daily for maintenance.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
None Documented
None Documented
Terminal elimination half-life is 36-48 hours in patients with normal renal function; prolonged to >100 hours in severe renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 30-40%, with enterohepatic circulation present.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Category C
Category C
Cardiac Glycoside
Cardiac Glycoside